Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19
Open Access
- 29 March 2022
- journal article
- editorial
- Published by Elsevier in SLAS Discovery
- Vol. 25 (10) , 1171-1173
Abstract
No abstract availableKeywords
Funding Information
- Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN 2017PAB8EM)
This publication has 19 references indexed in Scilit:
- A new coronavirus associated with human respiratory disease in ChinaNature, 2020
- Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trialTrials, 2020
- The relatively selective cyclooxygenase-2 inhibitor nimesulide: What’s going on?European Journal of Pharmacology, 2019
- Nimesulide-induced hepatotoxicity: A systematic review and meta-analysisPLOS ONE, 2019
- Amino Acid Transporters as Disease Modifiers and Drug TargetsSLAS Discovery, 2018
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronavirusesScience Translational Medicine, 2017
- Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common MarmosetThe Journal of Infectious Diseases, 2015
- Nimesulide binding site in the B0AT1 (SLC6A19) amino acid transporter. Mechanism of inhibition revealed by proteoliposome transport assay and molecular modellingBiochemical Pharmacology, 2014
- Tissue-Specific Amino Acid Transporter Partners ACE2 and Collectrin Differentially Interact With Hartnup MutationsGastroenterology, 2009
- Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with ReceptorScience, 2005